Glaxosmithkline Biologicals Sa

The Brigham and Women's Hospital, Inc.

Tomas Maira-Litran

Ralph Leon Biemans

Pierre Duvivier

Jan Poolman

Gerald B Pier

Philippe Denoel

The invention relates to compositions of a deacetylated poly N-acetylated glucosamine (dPNAG) of Staphylococci. The dPNAG may be isolated from natural sources or synthesized de novo. The invention also relates to the use of dPNAG as a vaccine for inducing active immunity to infections caused by, other related coagulase-negative or coagulase-positive Staphylococci, and other organisms carrying the ica (intracellular adhesion) locus. The invention further provides methods of use for antibodies directed to dPNAG, particularly for inducing passive immunity to the same class of infections.

Polysaccharide vaccine for staphylococcal infections

The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein.

Conjugation process for PNAG and a carrier protein

The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine group on PNAG to form a PNAG conjugate. Vaccines, methods of treatment using and processes to make an immunogenic composition comprising PNAG and Type 5 and/or 8 capsular polysaccharides are also described.

Growing community of inventors

Boston, MA, United States of America

Tomas Maira-Litran